Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

154.62 -0.07 (-0.05%)
Streaming Delayed Price Updated: 2:55 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J’s Latest Bankruptcy Plan
From Beasley Allen Law Firm
Via Business Wire
MarketBeat Week in Review – 7/15 - 7/19
Stocks took a breather to close the week, but corporate earnings and the next reading on the PCE index will help determine what direction the market moves next 
Via MarketBeat
Topics Economy
Exposures Interest Rates
This Medical Giant's Stock Rebounds: A 15% Upside Is the Minimum
Johnson & Johnson reported a solid quarter for Q2 but issued mixed guidance. The critical detail is that sequential growth continues, and YOY growth is on tap. 
Via MarketBeat
Exposures COVID-19
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024
From Johnson & Johnson
Via Business Wire
Johnson & Johnson reports Q2 2024 results
From Johnson & Johnson
Via Business Wire
NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors
From NKGen Biotech
Via GlobeNewswire
MarketBeat Week in Review – 7/8 - 7/12
Stocks took investors on quite a ride this week, with the S&P 500 hitting a new record high, then falling back on Thursday before rallying to end the week 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26
From Johnson & Johnson
Via Business Wire
Nasdaq vs. Dow Jones: A Detailed Breakdown of Stock Indexes
Nasdaq focuses on tech and growth stocks, offering high returns with higher volatility. Dow covers diverse sectors, providing steadier, lower-risk performance. 
Via MarketBeat
Topics Stocks
Exposures US Equities
AbbVie Stock: A Perfect Dip for Investors to Buy
ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors 
Via MarketBeat
Topics ETFs
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout. 
Via MarketBeat
Topics ETFs
Exposures COVID-19
Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue
From Beasley Allen
Via Business Wire
The Top 3 Sectors Poised For Growth This Summer
Communications, technology, and healthcare are the three hottest sectors for growth, but not all stocks will rise with the tides. 
Via MarketBeat
Topics ETFs
Johnson & Johnson Completes Acquisition of Proteologix, Inc.
From Johnson & Johnson
Via Business Wire
More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme
From Beasley Allen
Via Business Wire
Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products
From Beasley Allen
Via Business Wire
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
From FN Media Group LLC
Via GlobeNewswire
Talc Plaintiffs File Motion for Temporary Restraining Order to Limit Johnson & Johnson’s Use of Bankruptcy Strategy
From Beasley Allen Law Firm
Via Business Wire
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Completes Acquisition of Shockwave Medical
From Johnson & Johnson
Via Business Wire
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
From Numab Therapeutics AG
Via GlobeNewswire
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis
From Johnson & Johnson
Via Business Wire
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment
From Johnson & Johnson
Via Business Wire
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:ZLAB),(NASDAQ:NTBL),(NASDAQ:CRDF),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
Johnson & Johnson to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
Shockwave Medical Reports First Quarter 2024 Financial Results
From Shockwave Medical, Inc.
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: DecisionPoint Systems, Inc. (NYSE American - DPSI), AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Macatawa Bank Corporation (Nasdaq - MCBC), Shockwave Medical,
From Brodsky & Smith LLC
Via GlobeNewswire
Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
After a painful two-year selloff, Pfizer shareholders may have finally gained a foothold after the company delivered a solid Q1 2024 earnings report 
Via MarketBeat
Exposures COVID-19
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: DecisionPoint Systems, Inc. (NYSE American - DPSI), AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Macatawa Bank Corporation (Nasdaq - MCBC), Shockwave Medical,
From Brodsky & Smith LLC
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.